HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative - Takeaways - MDSpire

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative

  • By

  • Emmanuel Nazaire Essam Nkodo

  • Pooja Maheria

  • Eric Hurwitz

  • Alfred Jerrod Anzalone

  • Dongmei Li

  • Jessica Y Islam

  • Jing Sun

  • Cara D Varley

  • Zachary Butzin-Dozier

  • Sandra E Safo

  • Kaylyn Kirksey

  • Shukri A Hassan

  • Marlene Camacho-Rivera

  • Rena C Patel

  • Nada Fadul

  • On behalf of the National Clinical Cohort Collaborative USA

  • January 15, 2026

  • 0 min

Share

  • 1

    The study analyzed COVID-19 therapeutic access disparities among 7,806,412 patients, including 45,508 persons with HIV.

  • 2

    Persons with HIV had higher odds of receiving COVID-19 therapeutics compared to those without HIV, specifically remdesivir and nirmatrelvir/ritonavir.

  • 3

    Significant racial and ethnic inequities in treatment access were observed, particularly affecting American Indian, Hispanic/Latinx, and Black individuals with HIV.

  • 4

    The COVID-19 pandemic exacerbated existing health disparities, particularly among racial and ethnic minorities and individuals with comorbidities.

  • 5

    Access to COVID-19 treatments remains inequitable, highlighting the need for targeted interventions to address systemic barriers for vulnerable populations.

Original Source(s)

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative

  • by Emmanuel Nazaire Essam Nkodo, Pooja Maheria, Eric Hurwitz, Alfred Jerrod Anzalone, Dongmei Li, Jessica Y Islam, Jing Sun, Cara D Varley, Zachary Butzin-Dozier, Sandra E Safo, Kaylyn Kirksey, Shukri A Hassan, Marlene Camacho-Rivera, Rena C Patel, Nada Fadul, On behalf of the National Clinical Cohort Collaborative USA

  • January 15, 2026

Related Content

Long COVID Persistence and Surveillance Gaps Across 58 US Hospitals

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Long COVID as a network disorder: a mechanism-anchored framework for biological stratification and therapeutic targeting